Inflection Biosciences Announces Licensing of PIM kinase Inhibitors to Mysthera Therapeutics
Dublin, Ireland, August 21 2023 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...
top of page
Developing Innovative Therapeutics
Our Company
Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory disease. The pipeline comprises of IBL-101, an oral, pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease - partnered with Mysthera Therapeutics, IBL-202, selected from a series of unique dual mechanism kinase inhibitors and AUM302 (formerly IBL-302), partnered with AUM Biosciences.
bottom of page